Cencora

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article reads like a press release or a news article and may be largely based on routine coverage. Please help improve this article and add independent sources. (February 2018) This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (December 2020) (Learn how and when to remove this message)

Cencora, Inc.

Formerly	AmerisourceBergen Corporation (2001–2023)
Company type	Public
Traded as	NYSE: COR S&P 500 component
Industry	Pharmaceutical
Founded	2001; 23 years ago (2001) (merger between AmeriSource Health and Bergen Brunswig)
Headquarters	Conshohocken, Pennsylvania, U.S.
Area served	North America United Kingdom
Key people	Richard C. Gozon (Chairman) Steven H. Collis (President & CEO)
Products	Pharmaceuticals and pharmacy services
Revenue	US$262 billion (2023)
Operating income	US$2.34 billion (2023)
Net income	US$1.75 billion (2023)
Total assets	US$62.6 billion (2023)
Total equity	US$522 million (2023)
Owner	Walgreens Boots Alliance (25%)
Number of employees	c. 46,000 (2023)
Website	cencora.com
Footnotes / references Financials as of September 30, 2023[update].[1]

Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale company and a contract research organization that was formed by the merger of Bergen Brunswig and AmeriSource in 2001.^[2]